Cargando…
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
BACKGROUND: Germline mutations of the BRCA tumour suppressors have been associated with increased risk of pancreatic cancer. Clinical evidence suggests that these patients may be more sensitive to treatment with cisplatin. As the frequency of germline BRCA mutations is low, definitive experimental d...
Autores principales: | Lohse, I, Borgida, A, Cao, P, Cheung, M, Pintilie, M, Bianco, T, Holter, S, Ibrahimov, E, Kumareswaran, R, Bristow, R G, Tsao, M-S, Gallinger, S, Hedley, D W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522629/ https://www.ncbi.nlm.nih.gov/pubmed/26180923 http://dx.doi.org/10.1038/bjc.2015.220 |
Ejemplares similares
-
Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts
por: Lohse, Ines, et al.
Publicado: (2016) -
Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006) -
Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts
por: Chaudary, Naz, et al.
Publicado: (2017) -
BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells
por: Fan, S, et al.
Publicado: (2006) -
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
por: de Plater, L, et al.
Publicado: (2010)